Literature DB >> 11382200

Potential involvement of ubiquinone in myotonic dystrophy pathophysiology: new diagnostic approaches for new rationale therapeutics.

D Tedeschi1, V Lombardi, M Mancuso, F Martelli, C Sighieri, A Rocchi, S Tovani, G Siciliano, L Murri.   

Abstract

An impairment of mitochondrial function may contribute to the pathophysiology of myotonic dystrophy (MyD). Coenzyme Q10 (CoQ10) deficiency has been previously observed, even if in a restricted sample of patients. The aim of this investigation was to obtain more information about coenzyme Q10 and its relationships to the aerobic metabolism in a group of MyD patients. Serum CoQ10 appeared significantly reduced with respect to normal controls: 0.93 +/- 0.22 vs. 1.58 +/- 0.28 micrograms/ml (p < 0.05). Moreover, the results demonstrated an inverse tendency between CoQ10 levels and the CTG expansion degree. Basal blood lactate levels were significantly higher than controls (p < 0.05). A borderline inverse correlation between CoQ10 and lactate, corresponding to lactate threshold, was found. These data suggest a possible role of CoQ10 in the pathogenesis of MyD, which may be mediated by mechanisms of cellular damage common to the oxidative pathway. Therapeutic strategies may be devised by virtue of this rationale.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11382200     DOI: 10.1007/s100720070014

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  3 in total

1.  Myotonic Dystrophy type 1 cells display impaired metabolism and mitochondrial dysfunction that are reversed by metformin.

Authors:  Mikel García-Puga; Ander Saenz-Antoñanzas; Roberto Fernández-Torrón; Adolfo Lopez de Munain; Ander Matheu
Journal:  Aging (Albany NY)       Date:  2020-04-08       Impact factor: 5.682

Review 2.  Muscle wasting in myotonic dystrophies: a model of premature aging.

Authors:  Alba Judith Mateos-Aierdi; Maria Goicoechea; Ana Aiastui; Roberto Fernández-Torrón; Mikel Garcia-Puga; Ander Matheu; Adolfo López de Munain
Journal:  Front Aging Neurosci       Date:  2015-07-09       Impact factor: 5.750

Review 3.  Targeting Myotonic Dystrophy Type 1 with Metformin.

Authors:  Mikel García-Puga; Ander Saenz-Antoñanzas; Ander Matheu; Adolfo López de Munain
Journal:  Int J Mol Sci       Date:  2022-03-07       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.